FORT LAUDERDALE, Fla., Nov. 21 /PRNewswire-FirstCall/ -- Imaging
Diagnostic Systems, Inc., (OTC Bulletin Board: IMDS), a pioneer in human
laser optical imaging systems, announced that it will feature the new RSNA
Molecular Imaging Zone logo in its exhibit at RSNA 2006, to reflect the
role of optical technologies in RSNA's newly designated subspecialty.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGO )
The Molecular Imaging Zone is designed to introduce general
radiologists to molecular imaging, enabling them to learn the concepts at
their own pace. Among the topics featured in the MI Zone's debut are
optical imaging and cell tracking using targeted imaging agents. As part of
the Company's technical exhibit, IDSI will present work-in-progress results
of in-vivo human breast imaging using fluorescence compounds and will
feature the latest CTLM and multimodality breast imaging studies from
global sites.
Tim Hansen, Chief Executive Officer, Imaging Diagnostic Systems, said,
"We are pleased to be a part of the Molecular Imaging Zone. IDSI's many
pioneering efforts in optical molecular imaging have centered on deriving
functional information about molecular and cellular processes. As we have
successfully applied these techniques to women's health through our CT
laser breast imaging technology, we have also developed the LILA
capabilities for pre-clinical small animal imaging."
LILA is a helical, optical CT scanner that simultaneously acquires
optical attenuation and green fluorescent protein (GFP) image data. It
images fluorescence from GFP, expressed by the DNA of jellyfish, which has
been transfected into mammalian cells such as cancer tissue. LILA also
images the distribution of specific fluorescent probes in animals and
measures tissue optical absorption at near-infrared wavelengths to provide
an anatomic reference for the fluorescence distribution. In September 2005,
IDSI granted Bioscan, Inc. an exclusive worldwide license to manufacture
and distribute optical imaging equipment incorporating IDSI's Laser Imager
for Lab Animals (LILA) technology.
RSNA 2006 is the 92nd Scientific Assembly and Annual Meeting of the
Radiological Society of North America, which will be held November 26-30 in
Chicago, Illinois. The meeting, which attracts over 60,000 attendees, is
reporting pre-registration figures of 17,986 total health professionals,
including approximately 6,000 international attendees. IDSI will be
exhibiting in Hall A, booth #4702, McCormick Place South Building.
Imaging Diagnostic Systems is seeking FDA Premarket Approval (PMA) for
its Computed Tomography Laser Mammography (CTLM(R)) system to be used as an
adjunct to mammography. The FDA has determined that the Company's clinical
investigation is a non-significant risk (NSR) investigational device study
because it does not meet the definition of a significant risk (SR) device
under 812.3(m) of the investigational device exemptions (IDE) regulation
(21 CFR 812). The CTLM(R) system is the first patented breast imaging
system that utilizes state-of-the-art laser technology and patented
algorithms to create 3-D images of the breast. It is a non-invasive,
painless examination that does not expose the patient to radiation or
require breast compression. The CTLM system is limited by United States
Federal Law to investigational use only in the United States. Imaging
Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian
License, China SFDA approval, UL listing, ISO 9001:2000, ISO 13485:2003
certification and FDA export certification for its CT Laser Mammography
system.
As contemplated by the provisions of the Safe Harbor section of the
Private Securities Litigation Reform Act of 1995, this news release may
contain forward-looking statements pertaining to future, anticipated, or
projected plans, performances and developments, as well as other statements
relating to future operations. All such forward-looking statements are
necessarily only estimates or predictions of future results or events and
there can be no assurance that actual results or events will not materially
differ from expectations. Further information on potential factors that
could affect Imaging Diagnostic Systems, Inc., is included in the Company's
filings with the Securities and Exchange Commission. We expressly disclaim
any intent or obligation to update any forward-looking statements.
Investor Relations:
Rick Lutz
404-261-1196
lcgroup@mindspring.com
SOURCE Imaging Diagnostic Systems, Inc.
 back to top
Related links:
http://www.imds.com
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
CONTACT:
Rick Lutz, Investor Relations of Imaging
Diagnostic Systems, Inc., +1-404-261-1196, or
lcgroup@mindspring.com
|
